NCT00061516已完成3 期
Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 78
- 主要终点
- Mean Change from Baseline IOP
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of both BETAXON and AZOPT in pediatric patients. Patients will dose with study drug at 8 am and 8 pm daily for twelve weeks. Patients will have vision tested, slit lamp exam, blood pressure and pulse checks at each visit. Patients will have a dilated fundus exam and corneal measurements taken at first and last visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 1 Week 至 5 Years(Child)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Brinzolamide suspension, 1%
Experimental
Dosed twice daily for 12 weeks
干预措施: AZOPT (brinzolamide) (Drug)
Levobetaxolol suspension, 0.5%
Experimental
Dosed twice daily for 12 weeks
干预措施: BETAXON (levobetaxolol HCl) (Drug)
结局指标
主要结局
Mean Change from Baseline IOP
时间窗: Up to Week 12
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain PopulationMigraine DisordersHeadache, MigrainePediatricsNCT03055767University of California, Irvine17
已完成
3 期
Botox Injection for Lower Extremity Lengthening and Deformity Correction SurgeryLower Extremity Deformities, CongenitalUnequal Length of Limbs CongenitalNCT00412035Shriners Hospitals for Children125
已完成
3 期
Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular HypertensionGlaucomaOcular HypertensionNCT00061542Alcon Research105
已完成
2 期
Treatment With Xeomin Versus Botox in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral PalsySpastic Paraplegia and HemiparesisEquine and Equinovarus Foot DeformationCerebral PalsyNCT02188277Merz Pharmaceuticals GmbH64
Unknown
1 期
Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot StudyMajor Depressive DisorderDepressionNCT01239888The Alfred15
